interactions and what amino acids? Mutagenesis of amino acids at the interface between PDZ and the protease domains revealed some tantalizing clues. Three amino acids (Lys243, Arg256, and Asp320) in the PDZ domain were found to be particularly important, as their mutation led to drastically increased basal rate cleavage of RseA (Sohn et al., 2007) . In addition, Arg178 in the protease domain, which is highly conserved among DegS orthologs, was thought to be the key determinant in the allosteric switch from the inactive to active conformation.
These latest advances contribute to an improved model ( Figure 1 ) and make quantitative understanding of the OMP stress response possible. For example, the moderate binding affinities between the OMP peptides and DegS likely ensure a threshold for detection of the stress response: only when there is an accumulation of the unfolded OMP proteins. In addition, the wide range of binding affinities for DegS-4.6 µM for the YYF sequence and 130 µM for the YAF sequence (Sohn et al., 2007) -may set a different threshold for the accumulation of differing OMP proteins. It should be noted, however, that many unanswered questions remain. RseB, a periplasmic protein that binds to RseA, was shown to inhibit DegS-mediated cleavage of RseA in vitro regardless of the OMP peptides (Cezairliyan and Sauer, 2007) . The molecular basis for this inhibition remains to be investigated. How DegS overcomes RseB-mediated inhibition of RseA during the OMP stress response remains unclear. Periplasmic proteolysis of RseA by DegS is merely a prerequisite for the second cleavage of RseA by the membrane-embedded metalloprotease YaeL-why this is the case remains unknown.
DegS is a representative member of a family of PDZ-containing serine proteases (Clausen et al., 2002) . Does the allosteric mechanism observed for DegS apply to other family members? After all, these proteases share conserved domain structures and sequences and form trimers in solution. Similar to DegS, deletion of the PDZ domain makes human HtrA2 (a DegS homolog) more active (Li et al., 2002) . Therefore, it is tempting to speculate that the mechanism of activation described by Sohn et al. might be generally applicable to other members of this family of proteases. An agent that blocks tumor angiogenesis, growth, and metastasis without affecting normal tissues-whether used alone or in combination with currently approved drugs-would change the way we treat cancer. In this issue, Fischer et al. (2007) offer compelling evidence that a monoclonal antibody against placental growth factor (PlGF), a member of the VEGF family, has such potential in mice.
standard chemotherapy regimens can extend survival of patients with metastatic colorectal or lung cancer by 2 to 5 months with manageable toxicities. These results raise many critical questions (Jain et al., 2006) . First, why is such a combination effective against some malignancies, such as colorectal or lung cancer, and not against others, such as pancreatic cancer? Second, how can we extend survival beyond a few months in patients in which such a combination does work? Third, how can we minimize the adverse effects of blocking VEGF signaling? In this issue of Cell, Fischer, Carmeliet, and colleagues (Fischer et al., 2007) offer a potential solution to these challenges in the form of a monoclonal antibody (αPlGF) that neutralizes murine placental growth factor (PlGF), a member of the VEGF family. Only 300 papers have been published on PlGF, which was cloned in 1991 (Maglione et al., 1991) . In contrast, more than 21,000 papers have been published on VEGF, which was cloned 2 years earlier, in 1989 (Dvorak, 2006; Ferrara et al., 2004) . Human PlGF encodes four isoforms (PlGF-1 to PlGF-4), whereas mouse PlGF encodes a single isoform (PlGF-2). Unlike VEGF-deficient mice, which die during embryogenesis, PlGF-deficient mice develop normally. In a series of elegant experiments, Carmeliet and his group previously showed that loss of PlGF impairs pathological angiogenesis in adults, including new blood vessel formation associated with tumors (Luttun et al., 2002) . They also demonstrated that murine PlGF amplifies VEGF signaling in endothelial cells through VEGF receptor 1 (VEGFR-1) transphosphorylation of VEGFR-2 and that recombinant PlGF treatment stimulates revascularization of ischemic tissues (Autiero et al., 2003; Carmeliet et al., 2001; Luttun et al., 2002) . Based on these seminal studies, Carmeliet and colleagues put forth the hypothesis that an αPlGF monoclonal antibody could serve as a safer antiangiogenic agent than an αVEGF monoclonal antibody and could perhaps substitute for or augment the effect of anti-VEGF therapy. As PlGF levels are known to increase in the circulation of cancer patients receiving anti-VEGF treatment (Batchelor et al., 2007; Xu and Jain, 2007) , αPlGF could also counter this side effect of anti-VEGF therapy.
In this issue, Fischer et al. (2007) provide compelling evidence in support of this hypothesis ( Table 1) . The authors developed a specific blocking antibody against mouse PlGF-2 with no crossreactivity against the human PlGFs. To test the function of this antibody, they used mouse melanoma, pancreatic carcinoma, colon carcinoma, and lymphoma cell lines, all of which express abundant PlGF, and demonstrated that αPlGF inhibited tumor growth in both ectopic and orthotopic mouse tumor models. αPlGF also inhibited metastases of these tumors to the bile duct and lymph nodes as well as formation of ascites by an orthotopic pancreatic tumor. Furthermore, αPlGF enhanced the efficacy of the chemotherapeutic agents cyclophosphamide and gemcitabine in murine melanoma and pancreatic tumor models (Table 1) .
One of the major problems in antiangiogenesis therapy is the propensity for malignant tumors to become resistant to treatments targeted against individual angiogenic factors by switching to production of other angiogenic molecules. For example, in a clinical trial in rectal cancer patients, plasma levels of both VEGF and PlGF increased after treatment with the αVEGF monoclonal antibody bevacizumab alone (Willett et al., 2005) . The same phenomenon was observed in recurrent glioblastoma and in metastatic renal cell cancer patients receiving receptor tyrosine kinase inhibitors whose targets include the VEGFR-2 pathway (Batchelor et al., 2007; Motzer et al., 2006) . Fischer et al. (2007) hypothesized that this increase in VEGF and PlGF is secondary to hypoxia and necrosis caused by anti-VEGF treatments. Indeed, unlike αVEGFR-2 or soluble VEGFR-2 (sVEGFR-2), αPlGF treatment did not cause severe hypoxia or necrosis or increases in plasma or tumor levels of VEGF and PlGF. On the other hand, αPlGF treatment enhanced the antitumor effects of αVEGFR-2 and sVEGFR-2. It would be worthwhile to test whether monoclonal antibodies that block both murine PlGF and VEGF would produce a similar outcome. Another important issue is the toxicity of anti-VEGF agents. Although some side effects (such as hypertension) are often manageable with medication, rare but severe adverse effects have been reported, including thrombosis, bleeding, and gastrointestinal perforations (Verheul and Pinedo, 2007) . Most of these adverse effects are presumably downstream effects of blocking VEGF signaling via VEGFR-2 in endothelial cells of normal tissues. Quiescent blood vessels lack VEG-FR-1, and PlGF levels are negligible in normal tissues; thus, αPlGF, unlike αVEGFR-2, does not affect body weight or embryonic development. Treatment with αVEGFR-2, but not αPlGF, resulted in pruning of blood vessels in normal organs such as the thyroid gland. However, the combination of αPlGF and αVEGFR-2, while boosting therapeutic efficacy, did not further enhance the pruning of normal blood vessels. Thus, αPlGF appears to be a safer antiangiogenic agent than αVEGFR-2, opening up the possibility of its use in treating pediatric or pregnant cancer patients.
Like any groundbreaking work, this study raises many questions. The most important one from a translational point of view is the prevalence of PlGF expression in human tumors. VEGF levels are elevated in most human tumors and often correlate with prognosis. In contrast, elevated PlGF expression is restricted to a subset of tumors such as breast and gastric carcinomas (Fischer et al., 2007) . The low expression of PlGF in some tumors could be due to the aberrant methylation of the PlGF promoter (Xu and Jain, 2007) . On the other hand, PlGF is expressed by endothelial cells, leukocytes, and other stromal cells. Fischer et al. (2007) chose tumor cell lines that abundantly express PlGF, and so the antitumor effect of αPlGF could have resulted from targeting both malignant and stromal cells. What is the effect of αPlGF in human tumor xenografts in mice or in murine tumors in which PlGF expression is low in cancer cells? Fischer et al. (2007) have carefully dissected mechanisms by which αPlGF exerts its antiangiogenic and antitumor effects. They demonstrate that αPlGF blocks accumulation of macrophages in tumors and then suggest how this mechanism makes αPlGF a potent blocker of lymphangiogenesis and lymphatic metastasis. They attribute the inability of αVEGFR-2 to inhibit macrophage infiltration as contributing to the resistance of these tumors to αVEGFR-2 and thus propose that αPlGF treatment could be particularly valuable when combined with VEGFR-2 blockade.
Another question that needs to be addressed is how αPlGF enhances the outcome of chemotherapy. Does αPlGF normalize abnormal blood vessel formation and the microenvironment of tumors, resulting in better delivery and efficacy of chemotherapeutics? Does αPlGF target cancer and host cells that are dependent on VEGFR-1 signaling for survival? Does αPlGF block the recruitment of vascular modifying cells that express VEGFR-1? How does αPlGF affect the metastatic seeding of cancer cells at other sites in the body? Given that αVEGF is efficacious and approved for use with chemotherapy in two major metastatic diseases, scheduling αPlGF with αVEGF and/ or chemotherapy is likely to be the most important challenge in translating these findings to the clinic. In the meantime, αPlGF offers the possibility of an antiangiogenic agent that is potent and has little toxicity when combined with anti-VEGF strategies. Let us welcome this new kid on the antiangiogenic block and hope that it offers new opportunities for treating many different types of cancers.
AcKnowledGments R.K.J. is a consultant to AstraZeneca and Pfizer and a grantee of AstraZeneca.
